Antibody-drug conjugates show distinct safety profiles and improve quality of life in metastatic breast cancer.
HER2 (also known as ERBB2) is a key oncogene in breast cancer and is found in 2–4% of patients with non-small-cell lung ...
In a Chinese trial, trastuzumab rezetecan induced a 73% response rate in previously treated HER2-mutant non-small cell lung cancer (NSCLC). The safety profile of the novel antibody-drug conjugate was ...
OS Therapies, Inc. (NYSE-A: OSTX), a clinical-stage biotechnology company advancing immunotherapies and targeted drug conjugates for cancer treatment, announced the formation of subsidiary OS Drug ...
The partners will test Summit’s ivonescimab alongside Pfizer’s antibody-drug conjugates in hopes of finding “potentially ...
As OS Therapies prepares to take its bacteria-based lung cancer therapy to the FDA for approval, the biotech has been ...
News Medical on MSN1d
New antibody-toxin conjugate designed to stimulate immune-mediated eradication of tumorsResearchers at The University of Texas MD Anderson Cancer Center have developed a novel antibody-toxin conjugate (ATC) designed to stimulate immune-mediated eradication of tumors.
The firm is focusing on specialty chronic therapies like immunotherapy, antibody-drug conjugates, and gene therapy drugs, ...
Receiving Fast Track designation for PYX-201 from the FDA marks a significant milestone for Pyxis Oncology, recognizing our potential to address the significant medical need in R/M HNSCC. This ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback